Submit RFI/RFP
Request Consultation
FeaturedKaftrio Serious Impact on Mental health
With Kaftrio being used for treatment of patients with Cystic Fibrosis, comes serious negative impact on patient’s psychological state. As of 25 February 2025, the MHRA received 300…
Newsroom
News
301 articles
Featured
FeaturedNew Conditional Approval for Lymphoblastic Leukemia
The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for obecabtagene autoleucel (Aucatzyl)—a CAR T-cell therapy—for the treatment of adult patients with relapsed or…
FeaturedRethinking Fluoride: FDA Takes a Stand for Kids’ Health
The U.S. Food and Drug Administration (FDA) has taken the initiative to stop the use of concentrated ingestible fluoride present in prescription drugs of children. Toddlers or infants…
FeaturedFaster, Flexible Cancer Care: Nivolumab Newest Subcutaneous Injection Approval
As of 30 April 2025, a new formulation for Nivolumab has been approved by The Medicines and Healthcare products Regulatory Agency (MHRA) making the treatment process much simpler…
FeaturedHope For the Heart: Acoramidis Approved for Transthyretin Amyloidosis
The UK’s Medicines & Healthcare Products Regulatory agency has approved Acoramidis (Beyonttra) for the treatment of adult patients with cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM), including both wild-type…
FeaturedThe Blue Inhaler Trap: What Every Asthma Patient Should Know
Asthma Patients who rely solely on their blue inhalers may be putting their health at greater risk. That’s why The Medicines and Healthcare products Regulatory Agency (MHRA) is…
FeaturedFirst UK Approval for Friedreich’s Ataxia Treatment
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Omaveloxolone (Skyclarys) as the first-ever treatment for Friedreich’s ataxia in patients aged 16 and older, a major…
FeaturedA New Era in Managing Thyroid Eye Disease Patients
For years now Thyroid Eye Disease (TED) has been a struggle to anyone suffering from it, with limited treatment options available on hand & sometimes the need to…
FeaturedSmarter Pathways to Biosimilars
EMA’s continuous straining efforts to develop & improve biosimilar medicine has been ongoing for decades now. While still maintaining the strict European Union safety standards with the aim…
FeaturedFezolinetant risk of liver injury: Minimizing Liver Risk with New Guidelines
Close monitoring of drugs side effects is a necessity, since leaving it un attended can lead to serious complications that on the long run maybe hear to reverse.…
FeaturedA New Chapter in Research: UK Sets Clinical Trial Standards
A new chapter in in the UK medical research has begun which is more efficient, safer & smarter. With the biggest reform in over two decades. The UK…
FeaturedEMA Endorses AI Powered Tools Supporting Liver Biopsy Analyses
As AI continues to reshape the future of healthcare, a significant milestone has been achieved. The European Medicines Agency’s (EMA) human medicines committee (CHMP) has granted the first-ever…
FeaturedRelief in Reach: New Promise to Hemophilia Warriors
For most patients suffering from a chronic illness symptoms is of course their main struggling area, but what sometimes goes un noticed is the frequency & commitment to…
FeaturedNew Approval for Hard-to-Treat HER2-Positive Cancer Tumors
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the use of trastuzumab deruxtecan (Enhertu) for treatment of people with HER-2 positive cancers that has metastasized to…
FeaturedExpanded Therapeutic use of Kaftrio & Kalydeco in cystic fibrosis patients
Based on recent studies performed by the CHMP which included clinical trials, lab tests, real world evidence studies & bibliographical data. The European Medicines Agency has recommended to…
Ready to simplify your journey?
Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.
Submit RFI/RFP